GH Research PLC (GHRS) fair value: what the stock is really worth
We calculate from audited financials what GH Research PLC is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
- Compare price with fair valuebelow fair value = cheap, above = expensive
- Check the quality50 and up solid, 75 and up strong
- Watch it or check another stockalert when fair value or trend changes
At a glance
GH Research PLC
GHRS · US
Below-average quality, and trading another 582% above our fair value of $4.04.
As of Sep 8, 2026, the fair value of GH Research PLC is $4.04 per share against a price of $27.56, so the fair value sits 85% below the price. A model estimate from reported figures, not an analyst target.
Fair value as of: Sep 8, 2026
From 1 valuation models · updated 2 days ago
Share price −6.7% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($5.05). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range ($2.67 to $5.05) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 8, 2026.
How to read this chart
60‑month range $5.26 – $30.64 · fair‑value band $2.67 – $5.05 · the $27.56 price screens above the $4.04 fair value. Dashed = 300-day average. As of Sep 8, 2026.
Analysis
GH Research PLC (GHRS) currently trades at $27.56, while our model-based Fair Value estimate is $4.04, implying the stock looks roughly 582.1% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
It earns a return on equity of −19.7%. The balance sheet holds a net cash position of $246M. Fundamentals as of Sep 8, 2026
Scenario range: $2.67 (bear) to $5.05 (bull), the price of $27.56 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades near its 52-week high and 143% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −85%, GHRS screens richer than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
All 1 models by family
Notify me when GHRS reaches fair value
Put GHRS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Sep 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 73
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Full company description
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
GH Research PLC reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$48.3M in FY2025.
GHRS screens 582% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 632 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Sep 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $546.12 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $827.72 | $594.40 | −28% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,452,000 KRW | 1,055,793 KRW | −27% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE 22UA | €80.60 | €52.92 | −34% |
Compare GH Research PLC with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is GH Research PLC (GHRS) overvalued or undervalued?
What is the fair value of GHRS?
What is the quality score of GHRS?
What is the price target for GH Research PLC (GHRS)?
What is the GH Research PLC stock forecast for 2026?
What is the net profit margin of GHRS?
What is the intrinsic value of GH Research PLC (GHRS)?
Is GH Research PLC stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GHRS?
How much is GH Research PLC worth?
What do the bullish and bearish scenarios say about GHRS?
How solid is the balance sheet of GH Research PLC (GHRS)?
How far is GHRS from its 52-week high?
Which stocks are comparable to GH Research PLC?
Is GH Research PLC stock attractive at the current price?
How is the fair value of GHRS calculated?
Watch GH Research PLC in the live analysis
One click puts GH Research PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.